142896-15-9

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyridinecarboxylic acid, 2,6-dimethyl-, methyl ester is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Pyridinecarboxylic acid, 2,6-dimethyl-, methyl ester serves as an intermediate in the production of agrochemicals, aiding in the creation of substances that protect and enhance crop yields.
Used in Dye Industry:
4-Pyridinecarboxylic acid, 2,6-dimethyl-, methyl ester is utilized as an intermediate in the synthesis of dyes, contributing to the coloration and quality of various products.
Used as a Flavoring Agent:
This ester is employed as a flavoring agent in the food and beverage industry, enhancing the taste and aroma of products.
Used in Perfume Production:
As an intermediate in the production of perfumes, 4-Pyridinecarboxylic acid, 2,6-dimethyl-, methyl ester contributes to the creation of aromatic compounds that provide unique scents.
Used in Polymer and Adhesive Production:
4-Pyridinecarboxylic acid, 2,6-dimethyl-, methyl ester is used in the production of polymers and adhesives, playing a role in the development of materials with specific properties for various applications.

Upstream product

• 18206-06-9 2,6-dimethyl-4-pyridine carboxaldehyde 
• 1122-43-6 2,6-dimethyl-3-hydroxypyridine 
• 186581-53-3 diazomethane 
• 54221-93-1 2,6-dimethylisonicotinic acid 
• 42521-09-5 methyl 2,6-dichloroisonicotinate 
• 544-97-8 dimethyl zinc(II) 
• 113708-04-6 2,6-dimethylpyridine-4-carboxamide 
• 108-75-8 2,4,6-trimethyl-pyridine 
• 67-56-1 methanol 

Relevant academic research and scientific papers

KINASE ANTAGONISTS AND METHODS FOR MAKING AND USING THEM

Disclosed herein are small molecule compounds that are SGK1 antagonists, formulations and pharmaceutical compositions comprising the compounds, and methods of making and using them, for treating, ameliorating, preventing, reversing or slowing the progression of: a cancer, a tumor, a metastasis or a dysplastic or a dysfunctional cell condition responsive to inhibition of a kinase enzyme of the AGC group of kinases including SGK1, by administration of an AGC kinase inhibitor or antagonist.

Nickel-catalyzed carboxylation of aryl and heteroaryl fluorosulfates using carbon dioxide

The development of efficient and practical methods to construct carboxylic acids using CO2 as a C1 synthon is of great importance. Nickel-catalyzed carboxylation of aryl fluorosulfates and heteroaryl fluorosulfates with CO2 is described, affording arene carboxylic acids with good to excellent yields under mild conditions. In addition, a one-pot phenol fluorosulfation/carboxylation is developed.

Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors

The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.

Sulfone-mediated synthesis of polysubstituted pyridines

Base-mediated and/or palladium(0)-catalysed bis(allylation) of alkyl 2-(tolylsulfonyl)acetates gives 1,6-dienes, which upon ozonolytic cleavage of the double bonds and ammonolysis give 2,6-disubstituted pyridine-4-carboxylic esters. Decarboxylation of one

Novel rare earth metal cryptates which are not very sensitive to the fluorescence quenching

The invention relates to a process for reducing the fluorescence quenching caused by the measuring medium in a fluorescence assay, by introducing into said medium of rare earth metal cryptates which are not very sensitive to this fluorescence quenching, said rare earth metal cryptates comprising at least one pyridine radical which is substituted one or more times or unsubstituted. The invention also relates to novel rare earth metal cryptates which are not very sensitive to the fluorescence quenching caused by the measuring medium.

Not sensitive fluorescence quenching cryptate much new rare earth metal

The invention relates to a process for reducing the fluorescence quenching caused by the measuring medium in a fluorescence assay, by introducing into said medium of rare earth metal cryptates which are not very sensitive to this fluorescence quenching, said rare earth metal cryptates comprising at least one pyridine radical which is substituted one or more times or unsubstituted. The invention also relates to novel rare earth metal cryptates which are not very sensitive to the fluorescence quenching caused by the measuring medium.

LTA4 Hydrolase inhibitors

The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as proriasis, ulcerative colitis, IBD and asthma.